Latest news

ELSALYS BIOTECH expands its team to strengthen its strategy and the development of its programs

Mon, 01/30/2017 - 17:00

After having recently enriched its pipeline of therapeutic antibodies in oncology, ElsaLys Biotech strengthens its management team with the arriva

Read more

ELSALYS BIOTECH acquires rights of TRANSGENE’s ANTI-CD115 antibody

Thu, 12/15/2016 - 17:00

  • Initially developed by TRANSGENE, one of ELSALYS BIOTECH’s founding shareholders, this antibody inhibits a deleterious subpopulation of

Read more

ELSALYS BIOTECH expands its rights on CD160

Tue, 02/16/2016 - 17:00

  • Having acquired in June 2015 the assets of CD160 in the field of ophthalmology, ElsaLys Biotech strengthens its intellectual property an

Read more

ELSALYS BIOTECH announces the completion of the first instalment of a total fundraising amounting to € 5 million

Tue, 11/03/2015 - 17:00

IM Europe and Sofimac Partners are the main investors

 

Read more

The TYROMAB consortium, headed by ELSALYS BIOTECH, obtains 1.57 million euros from the single interministerial fund (fui)

Thu, 09/10/2015 - 17:00

Supported by ElsaLys Biotech, PX’Therapeutics, a subsidiary of the Aguettant group, and Centr

Read more

ELSALYS BIOTECH acquires a first-in-class antibody with a dual biological mechanism of action: anti-angiogenic and immuno-modulator

Thu, 07/02/2015 - 17:00

  • Developed so far by MABLIFE in ophthalmology, the anti-CD160 antibody has also a significant therapeutic potential in oncology.

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter

Subscribe now
Copyright 2018 ElsaLys Biotech SA

This website uses cookies to track its audience and improve its content.

By continuing to browse this website, you agree to the use of such cookies.